GDC-6988
Small molecule
Evidence outlook
Development stopped: Phase 1 study terminated
The drug's registered studies are all terminated, withdrawn or suspended (NCT06603246: terminated); none completed, so no evidence signal is assigned. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06603246 NCT06603246 · Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease Registry: NCT06603246 | 1 | Percentage of Participants With Adverse Events (AEs), with Severity Assessed by Division of Acquired Immunodeficiency Syndrome (DAIDS) Toxicity Grading Scale (From baseline up to 6 weeks); Percentage of Participants With Spirometry Abnormalities (From baseline up to 6 weeks) 2026-08-18 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Chronic Obstructive Pulmonary Disease: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| GDC-6988: this drug | Phase 1 | Small molecule | TMEM16A (Anoctamin-1) calcium-activated chloride channel | not yet graded | No reviewed efficacy summary in this indication | |
| Aclidinium Bromide (Tudorza Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT03022097: Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. NCT00891462: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) (Change from Baseline to 12 weeks): Aclidinium Bromide, 200µg 0.062 L (Standard Error 0.015) | Aclidinium Bromide, 400µg 0.099 L (Standard Error 0.015) vs Placebo -0.025 L (Standard Error 0.015) | |
| Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair) | ApprovedUS marketing discontinued | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | Partial signal | NCT03022097: Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) NCT02796677: Week 24, AB/FF 400/12 ug: 1-hour post-dose FEV1 vs aclidinium 400 ug +0.084 L (95% CI 0.051 to 0.117), p<0.0001; trough FEV1 vs formoterol 12 ug +0.055 L (95% CI 0.023 to 0.088), p=0.0009. Monotherapy primary: aclidinium vs tiotropium trough FEV1 +0.007 L (95% CI -0.021 to 0.035), non-inferior at the -50 mL margin (CT.gov posted results). | |
| Budesonide / Formoterol Fumarate (SYMBICORT) | Approved | Combination | Glucocorticoid receptor; Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | Reliable signal | NCT02465567: Rate of moderate/severe COPD exacerbations: PT010 (the trial's investigational triple therapy) reduced the rate by 24% vs glycopyrronium/formoterol fumarate (PT003) (p<0.001), and by 13% vs budesonide/formoterol fumarate (PT009) (p=0.003) NCT02497001: Primary 1, FEV1 AUC0-4 at week 24, BGF MDI vs BFF MDI: LS mean difference 116 mL (95% CI 80 to 152; p<0.0001), met. Primary 2, change from baseline in morning pre-dose trough FEV1 at week 24, BGF MDI vs GFF MDI: 13 mL (95% CI -9 to 36; p=0.2375), missed. Separate Europe/Canada analysis over 24 weeks: FEV1 AUC0-4 vs BFF MDI +104 mL (95% CI 77 to 131; p<0.0001) and vs BUD/FORM DPI +91 mL (p<0.0001); trough FEV1 vs GFF MDI +22 mL (95% CI 4 to 39; p=0.0139), all met. | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT04456673: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057) NCT03930732: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.01 exacerbation per participant-year (95% CI 0.931 to 1.301) | Dupilumab 300 mg q2w 0.776 exacerbation per participant-year (95% CI 0.645 to 0.934) | |
| Ensifentrine (Ohtuvayre) | Approved | Small molecule | PDE3/PDE4 | Reliable signal | NCT05743075: Placebo-corrected change from baseline in FEV1 AUC0-12h at Week 12: +110 mL for ensifentrine (p<0.0001) NCT04535986: Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 (Baseline (pre-dose on Day 1) and Week 12): Ensifentrine 0.0611 liters (Standard Error 0.01825) vs Placebo -0.0256 liters (Standard Error 0.0195) | |
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | NCT02164513: Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) NCT02345161: Co-primary 1, trough FEV1 change to week 24 (ITT): +142 mL with FF/UMEC/VI vs -29 mL with budesonide/formoterol (LS mean difference 171 mL, 95% CI 148 to 194; P<0.001), met. Co-primary 2, SGRQ total score change to week 24 (ITT): -6.6 vs -4.3 units (LS mean difference -2.2, 95% CI -3.5 to -1.0; P<0.001), met. Supportive week-52 analyses in the extension subset: FEV1 difference 179 mL (95% CI 131 to 226; P<0.001); SGRQ difference -2.7 (95% CI -5.5 to 0.2; P=0.065), not significant. | |
| Fluticasone Furoate / Vilanterol (Breo Ellipta) | Approved | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | Partial signal | NCT01313676: Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants missed | |
| Fluticasone Propionate / Salmeterol (Advair Diskus) | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | Weak signal | Featured results are non-efficacy only in this race | |
| Ipratropium | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | not yet graded | No reviewed efficacy summary in this indication | |
| Ipratropium / Albuterol | Approved | Small molecule | Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination) | not yet graded | No reviewed efficacy summary in this indication | |
| Mepolizumab (Nucala) | Approved | Monoclonal antibody | IL-5, Interleukin-5 (IL-5), ligand-neutralizing | Partial signal | NCT04133909: Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15) | |
| Olodaterol | Approved | Small molecule | Beta-2 adrenergic receptor | Reliable signal | NCT00782210: FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624). NCT00796653: Week 24, olodaterol 5 and 10 ug vs placebo: FEV1 AUC0-3h +0.129 and +0.154 L (both p<0.0001); trough FEV1 +0.053 L (p=0.0055) and +0.069 L (p=0.0003); TDI focal score in this study +0.402 (p=0.1999) and +0.419 (p=0.1818), not significant; TDI in the combined analysis +0.509 (p=0.0270) and +0.525 (p=0.0203) (CT.gov posted results). | |
| Olodaterol / Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Revefenacin (Yupelri) | Approved | Small molecule | Muscarinic receptors (antagonist) | Reliable signal | NCT05046795: Trough FEV1 on Day 85 (Baseline and Day 85): Revefenacin Inhalation Solution 175 mcg QD. 55.12 mL (Standard Error 23.974) vs Placebo Inhalation Solution QD. -95.78 mL (Standard Error 24.504) NCT02459080: Study 0126: trough FEV1 change at day 85 vs placebo +79 mL with revefenacin 88 µg (p=0.0003) and +146 mL with revefenacin 175 µg (p<0.0001). | |
| Roflumilast (Daliresp) | Approved | Small molecule | PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| Salmeterol (DISKUS) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT02172287: Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. | |
| Umeclidinium (Incruse Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Reliable signal | NCT02184611: Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) NCT01387230: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Baseline and Day 85): Placebo -0.007 Liters (Standard Error 0.028) | UMEC 62.5 µg 0.12 Liters (Standard Error 0.0257) | UMEC 125 µg 0.145 Liters (Standard Error 0.0268) | |
| Umeclidinium / Vilanterol | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | Reliable signal | NCT01777334: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) NCT01716520: Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type (Baseline and Day 14 of each treatment period (up to study day 83)): UMEC/VI 62.5/25 µg — Responder to UMEC, n=90, 90, 88: 0.337 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.331 Liters (Standard Error 0.0148); Responder to Neither, n=36, 37, 36: 0.13 Liters (Standard Error 0.0243) vs UMEC 62.5 µg — Responder to UMEC, n=90, 90, 88: 0.216 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.189 Liters (Standard Error 0.015); Responder to Neither, n=36, 37, 36: 0.077 Liters (Standard Error 0.0243) | VI 25 µg — Responder to UMEC, n=90, 90, 88: 0.201 Liters (Standard Error 0.0167); Responder to VI, n=99, 102, 100: 0.233 Liters (Standard Error 0.0147); Responder to Neither, n=36, 37, 36: 0.057 Liters (Standard Error 0.024) | |
| Astegolimab | Phase 3 | Monoclonal antibody | ST2 (IL1RL1) | Partial signal | NCT05595642: ARNASA (NCT05595642), primary endpoint annualized COPD exacerbation rate (AER) at 52 weeks: astegolimab showed a numerical 14.5% reduction vs placebo, not statistically significant missed NCT05037929: Annualized COPD exacerbation rate reduced by a statistically significant 15.4% vs placebo at 52 weeks with every-two-weeks dosing | |
| Beclomethasone Dipropionate / Formoterol Fumarate | Phase 3 | Small molecule | Glucocorticoid receptor; β2-adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow) | Phase 3 | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | No reviewed efficacy summary in this indication | |
| Depemokimab | Phase 3 | Monoclonal antibody | IL-5 | not yet graded | No reviewed efficacy summary in this indication | |
| Felcorekibart | Phase 3 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| HSK39004 | Phase 3 | Small molecule | Phosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4) | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 3 | Antibody-derived scaffold | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| REGEND001 | Phase 3 | Cell therapy | Airway epithelial regeneration (autologous basal cells) | Partial signal | No reviewed efficacy summary in this indication | |
| Tezepelumab (Tezspire) | Phase 3 | Monoclonal antibody | TSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizing | not yet graded | No reviewed efficacy summary in this indication | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Tozorakimab | Phase 3 | Monoclonal antibody | IL-33 | Partial signal | NCT06040086: Primary endpoint met: statistically significant reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and the overall population (MIRANDA, AstraZeneca, 2026-04-20). NCT05158387: Primary endpoint met: tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations vs placebo in former smokers and the overall population (TITANIA, 2026-03-27). | |
| TQC3721 | Phase 3 | Small molecule | PDE3/PDE4 | Partial signal | NCT06527144: Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026). | |
| Stapokibart | Phase 2/3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| 9MW1911 | Phase 2 | Monoclonal antibody | IL-33/ST2, ST2 (IL1RL1) | Weak signal | Featured results are safety only in this race | |
| Alvelestat | Phase 2 | Small molecule | Neutrophil elastase | Partial signal | NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | |
| AZD6793 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Dexpramipexole | Phase 2 | Small molecule | Eosinophil maturation/survival (mitochondrial) | not yet graded | No reviewed efficacy summary in this indication | |
| Glasmacinal | Phase 2 | Small molecule | Airway epithelial barrier integrity | Partial signal | NCT05516316: Primary endpoint (BALF IL-8 after inhaled LPS challenge, 375 mg EP395 daily for 3 weeks vs placebo) not met. BALF IL-6, TNF-alpha, MIP-1alpha, MIP-1beta and MCP-1 were lower and IL-33, IL-8, IL-1beta, neutrophil elastase and myeloperoxidase higher with EP395 (none statistically significant). Serum SP-D rose with EP395 (mean 148.8 to 183.0 ng/mL at 24 h, p=0.0007) but not with placebo. missed | |
| HRS-9821 | Phase 2 | Small molecule | PDE3/PDE4 | Weak signal | No reviewed efficacy summary in this indication | |
| Ocankitug | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| PBF-680 | Phase 2 | — | Adenosine A1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pegtarazimod | Phase 2 | Peptide | Complement C1q / neutrophil effectors (myeloperoxidase, NETosis) | not yet graded | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 2 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| RC1416 | Phase 2 | Multispecific antibody | IL-4 / IL-5 / IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| RSS0343 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Solizmestrocel | Phase 2 | Cell therapy | Regenerative/anti-inflammatory (MSC) | Weak signal | No reviewed efficacy summary in this indication | |
| Verekitug | Phase 2 | Monoclonal antibody | TSLP receptor | not yet graded | No reviewed efficacy summary in this indication | |
| WIN378 | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| XKH001 | Phase 2 | Monoclonal antibody | IL-25 | not yet graded | No reviewed efficacy summary in this indication | |
| KIT2014 | Phase 1/2 | Peptide | PDE3/PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| APG808 | Phase 1(overall) | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| BBT002 | Phase 1 | Multispecific antibody | IL-4Ralpha / IL-5 | not yet graded | No reviewed efficacy summary in this indication | |
| Frevecitinib | Phase 1 | Small molecule | JAK1/2/3/TYK2 | Weak signal | No reviewed efficacy summary in this indication | |
| GSK3862995 | Phase 1 | Monoclonal antibody | IL-33 | not yet graded | No reviewed efficacy summary in this indication | |
| PUR1800 | Phase 1 | Small molecule | Narrow-spectrum kinase (p38/Syk-family) | not yet graded | No reviewed efficacy summary in this indication | |
| REGEND007 | Phase 1 | Cell therapy | Airway basal layer stem cells | not yet graded | No reviewed efficacy summary in this indication | |
| Ensifentrine / Glycopyrrolate | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 60 furthest-along competitors are listed; 4 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
No upcoming readouts on record for this asset.